Boston Therapeutics Inc (OTCMKTS:BTHE)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as low as $0.02. Boston Therapeutics shares last traded at $0.02, with a volume of 24,000 shares changing hands.
The firm’s fifty day simple moving average is $0.02.
Boston Therapeutics (OTCMKTS:BTHE) last announced its quarterly earnings results on Monday, May 20th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About Boston Therapeutics (OTCMKTS:BTHE)
Boston Therapeutics, Inc, a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications.
Recommended Story: Why are gap-down stocks important?
Receive News & Ratings for Boston Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.